Adolescents and Young Adults with Cancer (AYAs): When a Diagnosis Comes During the Most Formative Years of Life

The unique psychosocial challenges, the invisible signs of distress, and Kapa3’s holistic response through the European MELODIC project.

A cancer diagnosis during adolescence or young adulthood often comes at a time when life is unfolding through some of its most creative and defining stages. Education, employment, romantic relationships, independence, starting a family, and planning for the future are all taking shape. A cancer diagnosis can abruptly interrupt this journey, creating a reality that is often difficult to comprehend, even for the young people experiencing it.

Adolescents and young adults with cancer, internationally referred to as AYAs (Adolescents and Young Adults), represent a distinct population within oncology. Their needs extend far beyond the treatment of the disease itself. They encompass identity, autonomy, relationships, sexuality, fertility, education, employment, financial security, and, above all, how they perceive their future and themselves.

When Life Is Put on Hold

For a young person, experiencing cancer can create the feeling that their personal life has come to a standstill while their peers continue moving forward. Friends pursue their studies, build careers, travel, develop relationships, and start families, while they may be coping with hospitalisations, treatments, fatigue, and restrictions on everyday activities.

This disruption can significantly affect their psychological well-being. Social isolation, changes in body image, concerns about sexuality and intimate relationships, and fears about potential effects on fertility are issues that may not always be easy to discuss with family members or even with the healthcare team.

At the same time, interruptions to education or employment can create financial uncertainty and undermine a young person’s sense of independence.

The impact of cancer, therefore, is not limited to the physical body. It extends to how young people perceive themselves, their identity, and their place within society.

Psychological Distress Is Not Always Visible: Recognising the Warning Signs

One of the most important challenges in caring for AYA patients is that psychological distress is not always immediately recognisable.

Distress may emerge at different stages of treatment, including after treatment has ended, and can manifest in various ways.

It may be expressed through anger towards the healthcare team, mistrust of treatment or medical recommendations, repeated questioning or, conversely, complete avoidance of questions.

It may also appear as delayed or missed appointments, difficulty adhering to treatment, excessive reliance on information found online, or reluctance to seek support from family members and social networks.

At other times, the signs are even more subtle: withdrawal from friends, reduced participation in activities, feelings of loneliness or hopelessness, or the belief that “no one can understand what I am going through.”

These behaviours should not automatically be interpreted as non-cooperation or lack of motivation. They may reflect emotional distress, uncertainty, fear, or unmet psychosocial needs that require further exploration.

This is why communication is a fundamental component of care.

An open-ended question, a safe and supportive environment, and, above all, a genuine willingness to listen without minimising a young person’s feelings can provide the starting point for identifying needs at an early stage.

Completing Treatment Does Not Always Mean the End of the Struggle

Another important message concerns the period following the completion of cancer treatment.

The end of oncology treatment is often accompanied by relief and optimism. At the same time, however, it can create a new sense of uncertainty or emptiness.

Frequent contact with the hospital and healthcare professionals gradually decreases, while young people are expected to return to everyday life and redefine their identity and future after cancer.

Fear of recurrence, changes in relationships, returning to work or education, and the need to reconsider personal goals may create new psychological challenges.

Psychological recovery, therefore, does not necessarily follow the same timeline as physical recovery.

Importantly, resilience and psychological distress are not mutually exclusive.

A young person may continue moving forward, pursuing their goals and rebuilding their life, while simultaneously experiencing fear, uncertainty, or emotional difficulties.

Recognising this complexity is essential to avoid unrealistic expectations that young people should immediately return to their previous lives or feel consistently positive once treatment has ended.

From Recognition to Meaningful Support and Effective Interventions

Addressing these needs requires an approach that sees the AYA patient as a whole person, not simply as someone undergoing cancer treatment.

Active listening, encouraging emotional expression, strengthening autonomy, and facilitating access to appropriate psychosocial support services are essential elements of comprehensive care.

Support may include psychological and social care, peer-support groups, counselling, and practical assistance related to employment, financial concerns, or social rights.

Individualisation is particularly important.

Not all young people require the same type of support, nor do they experience cancer in the same way.

Age, family circumstances, social environment, personal values, and life goals all contribute to shaping different needs and expectations.

Evidence-Informed Psychotherapeutic Approaches

Several psychotherapeutic approaches may help address the psychological and emotional challenges experienced by adolescents and young adults affected by cancer.

Cognitive Behavioural Therapy (CBT) can help young people identify and reframe unhelpful patterns of thinking, develop more adaptive coping strategies, and regain a sense of control during periods of significant uncertainty.

Acceptance and Commitment Therapy (ACT) emphasises psychological flexibility, the recognition and acceptance of difficult emotions, and engagement with personal values. This approach may be particularly relevant when illness has disrupted a young person’s priorities, identity, or future plans.

In parallel, meaning-centred approaches can support AYA patients in addressing existential concerns, changes in identity, and experiences of loss.

These interventions may help individuals integrate the experience of cancer into their evolving understanding of themselves and their lives, while rediscovering meaning, purpose, and personal direction.

The Importance of Peer Support

Peer support represents another valuable dimension of psychosocial care.

Connecting with people who have experienced similar challenges can reduce feelings of social isolation, strengthen the sense that “I am not alone,” and create opportunities for mutual understanding.

Peer relationships may also provide a supportive environment in which young people feel more comfortable discussing concerns that can be difficult to communicate with family members or healthcare professionals.

These forms of support should be adapted to individual circumstances and preferences.

Psychotherapeutic and psychosocial interventions need to be delivered flexibly, taking into account each person’s developmental stage, cultural and social context, values, and changing needs.

The therapeutic relationship, trust, respect for autonomy, and the active involvement of young people in decisions affecting their care are fundamental components of a genuinely person-centred approach.

MELODIC and the Need for More Human-Centred Cancer Care

This need lies at the heart of the European project MELODIC – Mental Health Support for Young Adults with Cancer, in which Kapa3 – Cancer Guidance Centre participates as a project partner.

MELODIC focuses on the mental health and well-being of young adults affected by cancer, aiming to strengthen the knowledge, skills, and support available to them, their loved ones, and the professionals involved in their care.

The project specifically addresses the needs of young adults aged 18–35 and seeks to promote a more integrated, supportive, and human-centred approach to oncology care.

Within the framework of MELODIC, Kapa3 has actively contributed to the co-development of educational materials, the development of the educational framework, and the pilot educational intervention in Greece.

Through this participation, Kapa3 supports the recognition of psychosocial needs and the development of knowledge and competencies among healthcare professionals working with young people affected by cancer.

This approach is directly aligned with the philosophy of holistic cancer care: mental health is not a separate or secondary concern but an integral part of the overall experience of living with cancer.

MELODIC also highlights the importance of interdisciplinary collaboration and the early identification of psychosocial needs.

By strengthening awareness and professional competencies, healthcare professionals can become better equipped to recognise signs of distress and refer young people to appropriate support services in a timely and coordinated manner.

From Identifying Needs to Developing Supportive Interventions

The MELODIC project promotes an approach that moves beyond identifying psychological challenges towards developing practical, person-centred interventions that respond to the everyday realities of young adults living with cancer.

Its broader framework recognises the value of psychosocial support, social connection, physical activity, and engagement with nature as complementary dimensions of well-being.

For Kapa3, participation in MELODIC reflects a wider commitment to connecting scientific knowledge with practical support and the lived experiences of people affected by cancer.

By contributing to European collaboration, educational activities, and the development of supportive interventions, Kapa3 seeks to help strengthen a model of cancer care that is more responsive to the individual, social, and emotional needs of patients.

This commitment also reflects the organisation’s broader work in patient navigation, health literacy, access to rights, and psychosocial support.

Because meaningful cancer care must extend beyond medical treatment and recognise the person behind the diagnosis.

Why Listening to Young People Matters

Meaningful care begins with a simple but fundamental principle: listening.

Listening to the young person who is afraid, even when they cannot express that fear directly.

Listening to the person who feels angry, withdraws from others, or struggles to follow their treatment plan.

Listening to those who appear to be coping well but may be experiencing greater emotional difficulties than they reveal.

Listening without judgement, without minimising emotions, and without assuming that the needs of all young people affected by cancer are the same.

Behind every diagnosis is a person who continues to have relationships, plans, dreams, ambitions, and a need for independence.

Through its participation in MELODIC, alongside its broader activities supporting people living with cancer, Kapa3contributes to promoting a model of care that does not end with the treatment of the disease.

A model that recognises psychological and social needs, strengthens patient empowerment, and builds bridges towards appropriate support.

A model that understands that recovery is not only about physical health but also about rebuilding confidence, identity, relationships, and the ability to imagine a future.

Because cancer care is not only about helping people recover from illness. It is also about supporting them, with dignity and understanding, as they rebuild the lives they want to live.


Learn More About MELODIC

The European project MELODIC – Mental Health Support for Young Adults with Cancer aims to promote mental health and well-being among young adults affected by cancer through interdisciplinary collaboration, education, and person-centred supportive interventions.

Kapa3 participates in the project, contributing to its activities in Greece and to the broader European effort to strengthen psychosocial cancer care.

For more information about MELODIC, its objectives, activities, and Kapa3’s participation, visit the dedicated section of our website:

https://www.kapa3.gr/melodic/

If you are a young adult aged 18–35 with lived experience of cancer and would like to learn more about the project or possible opportunities for involvement, please contact the Kapa3 team.

Kapa3 – Cancer Guidance Centre

Website: https://www.kapa3.gr
Email: info@kapa3.gr
Telephone: +30 210 5221424


Source

Ciampa, D., Mathew, L., Fulginiti, K., & Fortune-Kottis, S. (2026, August 11). Addressing unique psychosocial challenges in adolescent and young adult (AYA) patients with cancer. Oncology Central.

https://www.oncology-central.com/addressing-unique-psychosocial-challenges-in-adolescent-and-young-adult-aya-patients-with-cancer/

Further information:
European MELODIC Project – Kapa3
https://www.kapa3.gr/melodic/


Article edited by:
Elena Panopoulou
Sociologist, Kapa3 Tripoli Team

Email: elenak3team@gmail.com
LinkedIn: https://www.linkedin.com/in/elena-panopoulou-5061aa426

Modern Oncology: When Survival Is Not Enough

New therapies, “hidden” effects and the need to assess not only how long patients live, but how they live

Modern Oncology: When Survival Is Not Enough

New therapies, “hidden” effects and the need to assess not only how long patients live, but how they live

Modern oncology is changing at an unprecedented pace. Immunotherapies, antibody–drug conjugates (ADCs), bispecific antibodies and new targeted therapies are creating treatment opportunities that would have been unimaginable only a few years ago.

Cancer treatment is becoming increasingly personalised and tailored to the biological and molecular characteristics of each tumour, while overall survival is being extended for many people living with cancer.

Yet alongside this remarkable scientific progress, a critical question is emerging:

What does it really mean to live longer after — or with — cancer?

A recent Nature Medicine editorial, entitled “Oncology must confront hidden side effects”, highlights precisely this challenge. While cancer drug development is advancing at remarkable speed, the approaches used to record, assess and manage long-term treatment-related toxicities — and their impact on patients’ quality of life — have not evolved at the same pace.

When a “mild” side effect becomes a major burden

Therapeutic success can create a new reality: people are living longer, but some must also manage treatment-related adverse effects for months, years or even for the rest of their lives.

An adverse event classified clinically as low-grade is not necessarily insignificant to the person experiencing it.

A persistent rash, diarrhoea, stomatitis or other symptoms may substantially affect daily functioning, psychological wellbeing and social life when they continue over long periods.

Similarly, some immune-related adverse events associated with immune checkpoint inhibitors can become chronic, persist for years or even be irreversible.

This highlights an important limitation of the Common Terminology Criteria for Adverse Events (CTCAE), which are widely used to classify and grade treatment-related adverse events.

The duration of adverse events is not adequately reflected, while functional and psychological consequences may also remain outside traditional toxicity assessment.

As a result, what may be considered “manageable” according to conventional clinical criteria can feel very different to the patient living with it every day.

Quality of life cannot be an afterthought

A second important issue is the timing of quality-of-life evidence.

In some cases, quality-of-life findings are reported considerably later than the primary results of a clinical trial, and sometimes after a new drug has already been approved.

This means that patients making treatment decisions during the early years of a new therapy may not yet have a complete picture of how it could affect their daily functioning, emotional wellbeing and overall quality of life.

At the same time, the questionnaires and tools used to assess quality of life need to evolve continuously.

And this cannot happen without the direct involvement of patients themselves.

The experiences and priorities of people receiving treatment should form part of how treatment impact is assessed, rather than being treated as information that is added later.

The example of daraxonrasib

The Nature Medicine editorial highlights the pan-RAS inhibitor daraxonrasib as a telling example. The therapy has shown important survival benefits for patients with aggressive RAS-driven advanced pancreatic cancer, a setting in which treatment options have historically been limited.

At the same time, most patients experienced acneiform rash, with diarrhoea and stomatitis also reported as lower-grade treatment-related adverse events.

Full quality-of-life data — including information on daily functioning and emotional wellbeing — were not yet available because follow-up remained relatively short.

This example illustrates a much wider issue.

If we know that a therapy can significantly extend life, but we do not yet fully understand what that life will be like, an essential part of the information is missing from the conversation between patients and their healthcare teams.

This also has direct implications for informed consent.

Whenever evidence is available, patients need information not only about response rates and survival but also about the potential short- and long-term consequences of treatment for their everyday lives.

The same treatment is not experienced in the same way by everyone

The toxicity profile of a treatment is not identical for every patient.

It may vary according to the drug’s mechanism of action, a person’s physical condition, co-existing long-term conditions, genetic background and other individual characteristics.

Particular attention is needed for populations that have historically been excluded from, or underrepresented in, clinical trials, as their experiences of treatment-related toxicity may differ.

The editorial points, for example, to sex-related differences in adverse events associated with immunotherapy and racial disparities in adverse events observed with CAR-T cell therapy.

This makes real-world data particularly important.

Clinical trials remain fundamental to establishing the safety and efficacy of new treatments. However, broader use in everyday clinical practice may reveal treatment effects that were not fully captured in the populations included in initial studies.

One example is the bispecific antibody amivantamab in lung cancer, where the full extent and severity of some skin toxicities became clearer after a broader patient population was exposed to the treatment.

Moving beyond clinical silos

This changing landscape also demands a different approach to the organisation of cancer care.

The adverse effects of modern cancer therapies do not always fit within a single organ system or medical specialty.

Traditional clinical and disciplinary silos can limit the transfer of knowledge needed to identify, monitor and manage emerging toxicities effectively.

The response therefore needs to be interdisciplinary.

Collaborative networks, updated guidance, systematic reporting, dedicated registries and effective knowledge exchange are increasingly important so that new or rare adverse effects can be recognised early and managed appropriately.

Above all, the patient voice must be heard

Perhaps the most important change concerns how we define treatment success itself.

Survival remains a fundamental goal of oncology.

But it cannot be the only one.

We also need to understand whether people can work, move, sleep, eat, participate in family and social life, maintain as much independence as possible and manage the effects of treatment on their everyday lives.

In other words, we need to know not only how much time a treatment adds to life, but also what that time means to the person living it.

Patients should therefore not enter the process only at the end, as recipients of treatment.

Their perspectives need to be incorporated from the design of clinical trials and assessment tools through to post-approval monitoring and the real-world use of new cancer therapies.

From survival to living after — and with — cancer

Progress in oncology is undeniable, and it brings genuine hope.

The next challenge is to ensure that longer survival is accompanied by quality of life, functioning, meaningful information, participation and dignity.

Modern cancer care therefore needs to move beyond asking only:

“How much longer can this patient live?”

and give equal importance to another question:

“How will this person live during that additional time?”

For Kapa3, this discussion goes to the heart of truly person-centred cancer care: care that sees not only the disease and the treatment, but the person, their everyday life, their needs, their choices and the life that continues during and after cancer.

Source and references

Main source:
Nature Medicine. “Oncology must confront hidden side effects.” Volume 32, July 2026. Published online 8 July 2026. DOI: 10.1038/s41591-026-04554-9.

  1. Barron CC et al. Journal for ImmunoTherapy of Cancer. 2023;11.
  2. Gyawali B et al. Lancet Oncology. 2025;26–e89.
  3. O’Reilly EM et al. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2605555.
  4. Unger JM et al. Journal of Clinical Oncology. 2022;40:1474–1486.
  5. Rayapureddy AK et al. Journal of Clinical Oncology. 2026;44.
  6. Hines MR et al. Transplantation and Cellular Therapy. 2023;29:438.e1–438.e16.

find more s41591-026-04554-9